Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer

Radzikowska E., Szczepulska E., Chabowski M., Bestry I.

Source: Eur Respir J 2003; 21: 552-555
Journal Issue: March
Disease area: Interstitial lung diseases

Congress or journal article abstractPDF journal article, handout or slidesFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Radzikowska E., Szczepulska E., Chabowski M., Bestry I.. Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Eur Respir J 2003; 21: 552-555

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The incidence of bronchiolitis obliterans organizing pneumonia syndrome after radiation therapy for breast cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 220s
Year: 2001

Chronic eosinophilic pneumonia after radiation therapy for breast cancer
Source: Eur Respir J 2004; 23: 9-13
Year: 2004



Organizing pneumonia in the course of Herceptin therapy for breast carcinoma
Source: Eur Respir J 2002; 20: Suppl. 38, 62s
Year: 2002

Drug-induced ILD
Source: Annual Congress 2007 - PG5 - Interstitial lung diseases: known causes and systemic disorders
Year: 2007


CC7 Pneumonia, pneumonitis, or progressive disease during immunotherapy in lung cancer?
Source: Milan 2017 - Educational material
Year: 2017

First ever report of histologically proven bronchiolitis obliterans organizing pneumonia after antineoplastic treatment of a malignant pleural mesothelioma with cisplatin and pemetrexed
Source: Annual Congress 2011 - Pleural and mediastinal malignancies: management and rare clinical cases
Year: 2011

Clinical characteristic of lung cancer patients with interstitial pneumonia treated with chemotherapy or radiotherapy
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008


The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia
Source: Eur Respir J 2009; 33: 142-147
Year: 2009



Clinical course of pneumonia in lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 326s
Year: 2005

Chronic eosinophilic pneumonia after radiation therapy for breast cancer
Source: Annual Congress 2011 - Rare diffuse lung diseases
Year: 2011

Level of hypoferremia at patients with community-acquired pneumonia (CAP) and lung cancer
Source: Eur Respir J 2007; 30: Suppl. 51, 438s
Year: 2007

Treatment and prognosis of lung cancer associated with interstitial pneumonia
Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series
Year: 2010


Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan
Source: ERJ Open Res, 6 (2) 00184-2019; 10.1183/23120541.00184-2019
Year: 2020



Acute lung injury as a possible adverse drug reaction related to gefitinib
Source: Eur Respir J 2002 Jan 01;22(1):179-181
Year: 2003



Clinical features of organizing pneumonia primed by radiation therapy to the breast
Source: Annual Congress 2008 - Imaging of different lung diseases: clinical and experimental observations
Year: 2008


Lung cancer: the importance of seeing a respiratory physician
Source: Eur Respir J 2003; 21: 606-610
Year: 2003



How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018


Characteristics, incidence, risk factors, and practical management of pneumonitis associated with anti-PD-1 immunotherapy in patients with non-small cell lung cancer
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019

Combination therapy of gefitinib and CYP3A4 inhibitor on non-small-cell lung cancer patients with an EGFR mutation and carcinomatous meningitis
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013